4.7 based on 10reviewsView this provider's reviews
Patient satisfaction ratings and reviews are based on personal opinions. Before you choose any doctor you should take into account their background, training, specialized experience AND their patient satisfaction to ensure they are the right fit for you.
*Please verify this information when scheduling an appointment.
Learn about Dr. Hagan
My personal philosophy is to provide compassionate quality care, delivered in a caring environment, with the patient's well being first and foremost. My practice participates in clinical trials with Sarah Canon Research Insitute which allows me to offer my patients state of the art, cutting edge, exciting new drugs which offer hope for a better future.
No sanctions history found for the years that Healthgrades collects data.
0 Board Actions
No board actions found for the years that Healthgrades collects data.
Eastern Va Med School Norfolk
Medical School | Graduated 1986
Allegheny Genl Hospital
Residency Hospital | Completed 1989
Fellowship Hospital | Completed 1992
Awards & Recognition
Awards & Honors
Healthgrades Honor Roll
Fellow American College of Physicians,
Top Doc Richmond Magazine,
Media & Publications
A Comparison Between Gemcitatbine and the Matrix Metalloproteinase (MMP) Inhibitor BAY 12-9566 in Patients with Advanced Pancreatic Cancer. M. Moore, J. Hamm, P. Eisenberg, M. Dagenais, K. Hagan, etc. al.,,
Introduction of IL6 Gene Expression in Karposi's Sarcoma Cells. Jing Yang, M.Kelly Hagan, Margaret K. Offerman,
Updated Efficacy and Safety Assessment of First Line Therapy with Lapatinib, Trastuzumab and Paclitaxel in Her2+ Metastatic Breast Cancer. FJ Esteva, SX Franco, K Hagan et al.,
Regulations of Adhesion Molecule Expression in Karposi's Sarcoma Cells. Jing Yang, Yuelin Xu, Cheng Zhe, M.Kelly Hagan, Margaret K. Offerman,
An Evaluation of the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus Paclitaxel in First Line Her2+ Metastatic Breast Cancer. FJ Esteva, SX Franco, K Hagan et al.,
Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced Or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the NCIC.
MJ Moore, J Hamm, J Dancey, PD Eisenberg, M Dagenas, A Fields, K Hagan, et al,
Memberships & Professional Affiliations
Dr. Hagan does not have any memberships or affiliations listed. If you are Dr. Hagan and would like to add memberships or affiliations, please update your profile.